Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Valeant Pharmaceuticals International (VRX) Stock Price
News headlines about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have been trending somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 45.5905635610083 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Valeant Pharmaceuticals International’s (VRX) “Buy” Rating Reiterated at Stifel Nicolaus (wisdomsave.com)
- Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 (finance.yahoo.com)
- Cantor Fitzgerald Reiterates Buy Rating for Valeant Pharmaceuticals International, Inc. (VRX) (americanbankingnews.com)
- Valeant Pharmaceuticals International, Inc. (VRX) Short Interest Down 9.5% in July (americanbankingnews.com)
- Valeant Pharmaceuticals International, Inc. (VRX)- Stocks Skyrockets on Performance Assessment – NASDAQ Times (nasdaqtimes.com)
Valeant Pharmaceuticals International (NYSE VRX) traded up 1.34% during midday trading on Thursday, hitting $14.34. 21,846,271 shares of the stock traded hands. The company’s 50-day moving average is $16.27 and its 200-day moving average is $13.39. The company’s market cap is $5.00 billion. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.88) earnings per share. Equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.
A number of research firms have weighed in on VRX. Jefferies Group LLC set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Saturday, May 6th. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research note on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Canaccord Genuity set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Thursday, August 10th. Finally, Stifel Nicolaus restated a “buy” rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $17.31.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Valeant Pharmaceuticals International (VRX) Stock Price” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-valeant-pharmaceuticals-international-vrx-stock-price.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.